Literature DB >> 21889029

Gastric adenocarcinoma surgery and adjuvant therapy.

Sameer H Patel1, David A Kooby.   

Abstract

Gastric adenocarcinoma is one of the most common causes of death worldwide. Surgical resection remains the mainstay of therapy, offering the only chance for complete cure. Resection is based on the principles of obtaining adequate margins, with the extent of lymphadenectomy remaining controversial. Neoadjuvant and adjuvant therapies are used to reduce local recurrence and improve long-term survival. This article reviews the literature and provides a summary of surgical management options and neoadjuvant/adjuvant therapies for gastric adenocarcinoma.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21889029     DOI: 10.1016/j.suc.2011.06.009

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  6 in total

1.  Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC).

Authors:  S Keskin; I Yıldız; F Sen; F Aydogan; L Kilic; M Ekenel; S Saglam; B Sakar; R Disci; F Aykan
Journal:  Clin Transl Oncol       Date:  2012-10-02       Impact factor: 3.405

2.  Factors associated with early recurrence after curative surgery for gastric cancer.

Authors:  Wei-Ming Kang; Qing-Bin Meng; Jian-Chun Yu; Zhi-Qiang Ma; Zhi-Tian Li
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

Review 3.  Racial and ethnic disparities in gastric cancer outcomes: more important than surgical technique?

Authors:  Shaila J Merchant; Lily Li; Joseph Kim
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

4.  Microsatellite Alterations and Protein Expression of 5 Major Tumor Suppressor Genes in Gastric Adenocarcinomas.

Authors:  Won Hyuk Choi; Sookhyun Lee; Sungjin Cho
Journal:  Transl Oncol       Date:  2017-11-21       Impact factor: 4.243

5.  Regional and racial disparity in proximal gastric cancer survival outcomes 1996-2016: Results from SEER and China National Cancer Center database.

Authors:  Lulu Zhao; Penghui Niu; Dongbing Zhao; Yingtai Chen
Journal:  Cancer Med       Date:  2021-06-09       Impact factor: 4.452

6.  Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes.

Authors:  Yi Liu; Ke-Cheng Zhang; Xiao-Hui Huang; Hong-Qing Xi; Yun-He Gao; Wen-Quan Liang; Xin-Xin Wang; Lin Chen
Journal:  World J Gastroenterol       Date:  2018-01-14       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.